P18.09 The patients’ perspective on recurrent therapy in high-grade gliomas: Results of a prospective multicenter study on health-related quality of life
التفاصيل البيبلوغرافية
العنوان:
P18.09 The patients’ perspective on recurrent therapy in high-grade gliomas: Results of a prospective multicenter study on health-related quality of life
Objective: To assess impact of common recurrence therapy in high-grade glioma (HGG) patients on health-related quality of life (HRQoL) in an unselected cohort. Methods: We analyzed the completed European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and BN20) of 92 patients within one year after diagnosis of tumor recurrence of a HGG and respective treatment in a prospective cross sectional multicenter study. We evaluated the influence of re-radiation, 2nd and 3rd chemotherapies and number of recurrent surgeries on sum scores for functioning, symptoms and a total score as well as on sub-scores for functioning and neurological symptoms using multivariate mixed models and descriptive statistics. Results: Adjusting for Karnofsky-Performance-Score (KPS) and age, different recurrent therapies did not significantly impact HRQoL. Neither re-radiation nor recurrent surgery significantly influenced HRQoL. Patients receiving second-line chemotherapy showed moderately better physical and role functioning as well as less motor dysfunction than patients receiving third-line chemotherapy. Comparing HRQoL after second-line chemotherapies, patients receiving Temozolomide (TMZ) 7/7 demonstrated a moderately better outcome for cognitive functioning and less communication deficits (p=0.055) than patients treated with Bevacizumab (Bev). Regarding number of recurrent surgeries, we found stable HRQoL scores until 2nd recurrent surgery, whereas after 3rd recurrent surgery HRQoL decreased. Conclusion: Our data show that the currently available treatment options have no negative impact on HRQoL. Thus, treatment decisions can be made individually, without fear of risking HRQoL for better survival. Only, the 3rd recurrent surgery remains a very individual decision even in younger patients with high KPS. However, due to the cross sectional character of the study and the heterogeneity of our patient cohort with recurrent HGGs, further prospective studies are required.
